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Abstract
Background: Childhood obesity and overweight are among the greatest health challenges in the pediatric
population. Obese individuals exhibit marked differences in the composition of the intestinal microbial community
as compared to lean subjects. These changes in the gut microbiota precede the clinical manifestation of
overweight. Convincing experimental data suggest a causal role for intestinal microbes in the development of
obesity and associated metabolic disorders.
Discussion: Exposure to antibiotics exerts a devastating impact on the intestinal microbial community. Epidemiological
studies have provided evidence indicating that early or repeated childhood exposure to antibiotics is associated with
increased risk of overweight later in childhood but the causal role of this exposure in obesity development is not clear.
However, data from studies conducted using experimental animal models indicate that antibiotic-induced changes in
the gut microbiota influence host metabolism and lead to fat accumulation. The intestinal microbiota perturbation
caused by antibiotic exposure in the perinatal period appears to program the host to an obesity-prone metabolic
phenotype, which persists after the antibiotics have been discontinued and the gut microbiota has recovered. These
observations may have serious implications in the clinical setting, since a substantial number of human infants are
subjected to antibiotic treatment through the mother during delivery or directly in the immediate neonatal period. The
clinical significance of these exposures remains unknown.
Summary: Prudent use of antibiotics is paramount not only to reduce the propagation of antibiotic-resistant organisms
but also to minimize the potentially detrimental long-term metabolic consequences of early antibiotic exposure.
Improved means of reliably detecting neonates with bacterial infection would reduce the need for empirical antibiotic
exposure initiated based on nonspecific symptoms and signs or risk factors. Finally, means to support healthy microbial
contact in neonates and infants requiring antibiotic treatment are needed.
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Background
The increasing prevalence of childhood obesity is one of
the greatest challenges facing medical professionals
caring for infants and children. According to a recent
report from the United States, more than one in six
children and youths between the ages of two and 19
years are obese and more than one in three are over-
weight [1]. Overweight and obese children are at a high
risk of becoming obese adults [2]. The detrimental
health consequences of obesity – increased risk of
metabolic and cardiovascular disease, musculoskeletal
problems as well as psychosocial issues – may manifest
already in childhood and become more prevalent with
increasing age. Effective strategies for reducing the risk
of obesity are desperately needed. Devising such means
is dependent on an improved understanding of the
factors involved in obesity development. Recent data
suggest that the developmental pathway leading to obes-
ity may begin already in infancy and that childhood
overweight is a strong predictor of later obesity [3]. Early
life programming towards a phenotype prone to obesity
may occur as a result of intrauterine or extrauterine
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influences [3], some of which may be amenable to inter-
vention. As discussed in detail below, reducing antibiotic
exposure in the perinatal period or in early infancy,
which has recently been associated with an increased
risk of obesity development, may be one means of com-
batting the obesity epidemic.
Overweight and obesity are highly hereditary because
of both genetic predisposition and learned behavioral
traits. However, hereditary factors fail to explain the
massive increase in the prevalence of obesity in popula-
tions across the globe. The simple proximal explanation
for obesity is excessive energy intake in comparison to
energy expenditure. The obesity epidemic may accord-
ingly be explained by changes related to lifestyle which
have occurred during the past decades - our increasingly
sedentary way of life combined with the all-to-common
Western diet high in fat, carbohydrates and energy but
low in fiber. Recent advances in scientific research have
revealed intriguing mediating factors between the diet,
host energy metabolism and the obese phenotype.
Namely, the indigenous intestinal microbiota has been
suggested to not only be influenced by diet but also to
play a causal role in the development of obesity
(reviewed in [4]).
The association between the composition of the intes-
tinal microbiota and obesity has been demonstrated by
studies showing differences in gut microbiota compos-
ition between obese and lean humans [5, 6] and more so
in experimental animals. Obesity is associated with an
increased abundance of the phylum Firmucutes and a
decrease in Bacteroidetes [5]. These gut microbiota al-
terations are at least partially attributable to diet, since
studies conducted using experimental models have
demonstrated that animals fed a western-type diet not
only display excessive weight gain but exhibit an increase
in intestinal Firmicutes and a decrease in Bacteroidetes
resembling the changes seen in obese humans [7].
Conversely, weight loss resulting from a low-energy diet
is accompanied by a shift in gut microbiota composition
to resemble that of lean individuals with a decrease in
Firmicutes and an increase in Bacteroidetes [5]. Con-
suming a Western-type diet is associated with reduced
gut microbiota diversity and higher abundance of poten-
tial pathogens in both experimental animals and human
subjects [8, 9]. These diet-induced changes in gut micro-
biota are most likely caused by altered availability of
substrates for different bacteria, but there are also data
indicating that an average Western diet contains fewer
viable microbes than a diet that is in accordance with
current recommendations [10]. These data conjointly
demonstrate an intimate association between the diet,
obesity and the gut microbiota. Interestingly, there also
appears to be a causal network linking intestinal mi-
crobes to the development of obesity.
The direct causal role of intestinal microbes in the de-
velopment of overweight and obesity has been demon-
strated in experimental studies in which the obese
phenotype may be transferred to germ-free animals
merely by colonizing them with the gut microbiota from
obese animals [7] or humans [11]. The mechanisms by
which gut microbes may induce weight accumulation
have also begun to unravel. The intestinal microbiota as-
sociated with obesity has been shown to increase intes-
tinal energy uptake from the diet [12] and its storage in
the host [13]. Furthermore, gut microbes appear to
modulate the expression of several host genes associated
with metabolism at least in part via microbial metabo-
lites including short chain fatty acids [reviewed in 4], the
production of which is influenced by dietary substrates.
The low-grade inflammation characteristic of obesity
and metabolic disease may also be induced and propa-
gated by interaction with certain intestinal microbes [4].
It is also of note that prospective clinical studies have
shown that changes in gut microbiota composition pre-
cede the development of overweight and obesity and
may be observed already in early infancy [14–16]. In
particular, a high abundance of intestinal bifidobacteria
in early life appears to be associated with lower risk of
overweight [15, 16], whereas high amounts of Bacter-
oides fragilis increase the risk of obesity development
[14]. It is therefore likely that factors that exert an im-
pact on gut microbiota composition in early life may
also modulate the risk of obesity development. As al-
luded to above, a diet rich in energy and fat is known to
divert the intestinal microbial population toward a com-
position, which may promote weight gain [7]. Con-
versely, a diet rich in fermentable but non-digestible
carbohydrates has been shown to alleviate obesity in
children via modulation of the gut microbiota [17]. The
purpose of this paper is to discuss the potentially
detrimental effects of non-dietary factors and particu-
larly exposure to antibiotics, which may disrupt the gut
microbiota in early life and consequently increase the
risk of obesity in children.
Discussion
Antimicrobial agents are among the most frequently
used pharmaceuticals in infants and children. Cox and
Blaser have recently estimated, that by two years of age,
children in the United States have on average received
nearly three courses of antibiotics and the number of
courses increases to approximately ten by the age of ten
years [18]. It is likely that these figures are relatively
similar for other developed countries, albeit considerable
differences in the frequency of antibiotic use have been
reported between countries and regions. The use of anti-
biotics is particularly prevalent in the perinatal period.
Intrapartum antibiotic prophylaxis is administered to the
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mother to prevent preterm birth and to reduce the risk
of maternal and neonatal infections. According to recent
publications [19, 20], 33–39 % of newborn infants are
exposed to antibiotics through the mother during deliv-
ery. In the immediate neonatal period, empirical anti-
biotic use is also frequent because of the high risk of
invasive bacterial infections in the neonate and the diffi-
culty of accurately identifying newborn infants with
septicemia. According to current recommendations [21],
all symptomatic neonates and certain asymptomatic in-
dividuals with a high risk of bacterial infection should
receive empirical antibiotic therapy. Consequently, more
than 5 % of neonates have been reported to receive anti-
biotics [20] even though the incidence of culture-proven
sepsis in newborn infants is less than one in one thou-
sand neonates [22]. The well-known untoward conse-
quences of antibiotic exposure include the propagation
of microbial antibiotic resistance and financial cost. We
are only beginning to understand the potentially detri-
mental long-term impact of early antibiotic exposure on
the intestinal microbiota and child health.
Given the mechanism of action of antimicrobial
agents, it is hardly surprising that antibiotic therapy in-
flicts a profound impact on intestinal microbial ecology
[23, 24]. In adults, the gut microbiota is thought to be
restored to its steady state relatively rapidly after initial
perturbation when antibiotic exposure is discontinued,
but antibiotic-associated diarrhea, particularly that
caused by Clostridium difficile, is a relatively common
complication of treatment. Nonetheless, there are data
suggesting that more prolonged gut microbiota alter-
ations may result from repeated antibiotic exposure [24]
and even a single seven-day course of clindamycin has
been reported to induce gut microbiota changes detect-
able two years after exposure in healthy volunteers [25].
Considerably less is known about the impact of anti-
biotic exposure on the developing intestinal microbiota
in infants and young children.
Antibiotic exposure in the neonatal period has a con-
siderable impact on early gut microbiota development.
In a study of nine term neonates subjected to treatment
with ampicillin and gentamicin, this antibiotic exposure
was associated with an increase in fecal Proteobacteria
and a decrease in Actinobacteria and particularly Bifido-
bacterium species at four weeks of age as compared to
non-exposed neonates [26]. The higher number of fecal
Proteobacteria in antibiotic-exposed infants persisted
until the end of the follow-up at eight weeks of age while
the abundance of Actinobacteria had recovered by that
time point. Similar results have been reported by
Arboleya and co-workers [27], who found that both
intrapartum and neonatal antibiotic exposure increased
the abundance of fecal Enterobacteriacaea during the
first three months of life. It is of note that the impact of
maternal intrapartum antibiotic administration on the
breast milk microbiota or the significance of neonatal
antibiotic exposure via breast milk are currently not
known. In preterm infants, empirical antibiotic therapy
based on a clinical suspicion of infection in the first
week of life resulted in a higher relative abundance of
Enterobacterium species and lower gut microbiota diver-
sity at the age of three weeks [28]. The clinical signifi-
cance of the overrepresentation of Proteobacteria and
Enterobacterium species in particular is not known.
Nonetheless, there are compelling data indicating that
early life antibiotic exposure markedly increases the risk
of overweight and obesity in later life.
A number of well-conducted epidemiological studies
suggest that antibiotic exposure in infancy is associated
with a higher body mass index (BMI) [29, 30] as well as
an increased risk of overweight [31, 32] and obesity [33]
later in childhood. A close reading of these reports reveals
that exposure to antibiotics appears to be particularly det-
rimental during the first six months of life [29–31]. In an
epidemiological study of more than 11,000 children from
the United Kingdom, antibiotic exposure during this time
period significantly increased the risk of overweight at
38 months of age (OR 1.22 after adjusting for potential
confounding factors; p = 0.029). Interestingly, boys may
be more affected by early antibiotic exposure than girls
[31, 32]. Antibiotic exposure during the first six months
of life was associated with overweight at the age of two
years in boys (adjusted OR 1.34 with 95 % CI 1.06–
1.66) in a cohort study of 12,000 children from Finland
[31] but the association was not detected in girls
(adjusted OR 1.16 with 95 % CI 0.87–1.56). Further-
more, a dose-response relationship pertaining to the
number of courses of antibiotics during the first two
years of life and the risk of childhood obesity was ob-
served in a cohort of more than 64,000 children from
the United States [33]. These epidemiological studies
based on tens of thousands of subjects clearly demon-
strate an association between early antibiotic exposure
and the development of overweight. However, establish-
ing a causal link between the two is more difficult.
A potential confounding factor in the reports indicat-
ing an association between early antibiotic use and sub-
sequent overweight or obesity are the infections because
of which the antibiotic therapy was initiated. The large
epidemiological studies published thus far have based
their estimates of antibiotic exposure either on prescrip-
tion records [31–33] or parental questionnaires [30] or
interviews [29]. It is reasonable to assume that most of
the antibiotic courses in these studies have been targeted
against infections of the respiratory tract, ears, skin and
urinary tract. Infectious disease in early childhood has
been suggested to play both a causative and protective
role in the development of chronic diseases such as
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asthma and allergic disease and type I diabetes mellitus
[34]. Interestingly, childhood chronic diseases such as
asthma [35] and inflammatory bowel disease [36] have
also been linked to antibiotic exposure in infancy but it
is not clear whether the antibiotics or the infections for
which they have been prescribed play a causal role in
their development. A recent report suggests – contrary
to what has previously been thought - that infectious
disease per se and not antibiotic use increases the risk of
psoriasis in the pediatric population [37]. Similar causal
patterns may also be involved in the development of
obesity since aberrant immune activation and a low-
grade inflammatory state are hallmarks of obesity and
metabolic disease. It is therefore possible that antibiotic
use is merely a marker for infectious or immunomodula-
tory events playing a role in the pathogenetic pathway
leading to weight accumulation. Investigating the impact
of antibiotic exposure on the development of disease in
infants or children not suffering from infectious disease
in randomized clinical trials is not possible for obvious
ethical reasons. Evidence of antibiotic exposure in the
absence of infection is thus needed from both epidemio-
logical studies and experimental animal models to estab-
lish a causal connection between antibiotic exposure and
the development of obesity.
A substantial number of subjects are exposed to anti-
microbial therapy without evidence of infection during
the perinatal period [20]. The wide-spread – and often
well-justified - practices of prophylactic or empirical
antibiotic use during delivery and in the immediate neo-
natal period offer a unique opportunity to study the
impact of early antibiotic exposure without the con-
founding effect of concomitant infection. Large-scale
studies with clinical outcome measures using such an
approach have to our knowledge not been published and
it is likely that the data acquisition methods in the
epidemiological studies discussed above [29–33] are not
sensitive to antibiotics administered immediately before
and after birth. Unpublished results from our laboratory
suggest that antibiotic use both during delivery and in
the neonatal period in infants not suffering from infec-
tions results in perturbations in intestinal microecology
during the first six months of life. However, the clinical se-
quelae of this aberrant gut colonization are not known.
It is well-established that other disturbances in peri-
natal microbial contact may increase the risk of obesity.
Infants born by caesarean section (CS) delivery do not
acquire the physiological inoculum of colonizing mi-
crobes from the birth canal and maternal gut that vagi-
nally born infants receive. Substantial differences in gut
microbiota between infants born by CS or through the
vaginal route have been reported in early infancy [38]. In
the immediate neonatal period, vaginally delivered new-
borns are colonized by maternal vaginal lactobacilli
whereas maternal skin microbes are detected in the feces
of individuals born by CS [38]. The differences in gut
microbiota composition between vaginally and CS
delivered children extend until the age of seven years
[39]. The clinical significance of this phenomenon is
demonstrated by a recent systematic review and meta-
analysis of epidemiological studies indicating that the
risk of childhood obesity in infants born by CS is 1.34-
fold (95 % CI 1.18–1.51) as compared to vaginally-born
subjects even if maternal BMI is taken into consider-
ation as a confounding factor [40]. It should be borne
in mind that in most centers prophylactic antibiotics
are administered to mothers undergoing CS. According
a Cochrane systematic review, antibiotic use before
elective CS reduces infectious complications in the
mother but its effects on the child are unknown [41]. It
is possible that at least a part of the reported associ-
ation between CS delivery and the risk of obesity may
in fact be mediated by antibiotic exposure. In support
of this notion, antibiotic use during pregnancy and CS
delivery appear to have an additive effect on BMI in
childhood [42].
The strongest corroboration for the hypothesis of early
antibiotic exposure causally increasing the risk of later-
life obesity stems from experimental studies conducted
using animal models. A series of experiments conducted
in Dr. Blaser’s laboratory at the New York School of
Medicine has demonstrated that exposure to low-dose
antibiotics from weaning results in increased fat-mass
accumulation in mice [43]. This increase in adiposity ap-
pears to be mediated by antibiotic-induced changes in
gut microbiota composition leading to increased short-
chain fatty acid production and altered host metabolism
including upregulation of genes involved in lipogenesis.
The observations according to which antibiotic exposure
at a subtherapeutic dose may increase weight accumula-
tion are highly relevant given the fact that production
animals are fed antibiotics in order to increase weight
gain in many countries and, as a result, human subjects
may be exposed to low-dose antibiotics by consuming
meat products.
A subsequent report from the same laboratory has
further increased our understanding of these phenomena
[44]. Maternal exposure to low-dose penicillin during
late gestation and lactation had a more pronounced
impact on weight and fat accumulation than direct
exposure after weaning. These data imply that there is a
critical time window in which antibiotic exposure may
be particularly detrimental. Male mice were more pro-
foundly affected than females by perinatal antibiotic ex-
posure, which is consistent with the epidemiological
data showing increased risk of overweight and obesity in
antibiotic-exposed boys discussed above. The fact that
the obese phenotype observed after antibiotic exposure
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is dependent on the gut microbiota is demonstrated by
experiments showing that fat accumulation may be in-
duced in non-exposed germ-free animals by colonizing
them with the altered gut microbiota from antibiotic-
exposed mice. Finally, and perhaps most alarmingly, it
appears that early antibiotic exposure may permanently
program host metabolism to an obese phenotype, since
the animals remained fat after the antibiotic exposure
was discontinued even when the gut microbiota recov-
ered to resemble that of normal-weight mice.
Summary
The association and possible causal relationship between
early-life antibiotic exposure and the development of
overweight and obesity raise concerns about current
medical practices but may also provide opportunities to
combat the obesity epidemic. It is clear that antibiotics
are often used for the treatment of conditions, which are
known to primarily be of viral origin or in instances
where there is little or no evidence of efficacy. Prudent
use of antibiotics is paramount to limit the propagation
of antimicrobial resistance in pathogens. Fortunately,
there are data indicating that antibiotic use in children
has reduced during recent years [45]. Research assessing
the safety and efficacy of antimicrobial therapy should
address the long-term impact of the interventions. In
particular, prophylactic antibiotic use in the perinatal
period should be subjected to rigorous scrutiny.
According to current recommendations, newborn in-
fants are to be treated with empirical antibiotic therapy
based on non-specific symptoms and signs of infection
or if the risk of infection has been estimated high
based on factors such as maternal chorionamnionitis
or colonization with group B Streptococcus [21]. These
practices are necessary even though they result in
antibiotic exposure in a large number of non-infected
neonates, because of lack of specific and sensitive
markers to detect infection early in the course of
disease. Developing such means would result in a sig-
nificant reduction of antibiotic use during the first days
of life and, given the potentially unfavorable long-term
effects of early antibiotic exposure, might entail a
considerable health impact.
Antibiotic therapy is often a necessary and life-saving
intervention in infants and children suffering from
bacterial infection. Even with improved diagnostic
methods and prudence in assessing the need for
antibiotics, a considerable number of subjects need to be
exposed to these drugs. To minimize the long-term risks
involved with early antibiotic exposure, adjunct therapies
aiming to alleviate its detrimental impact on the gut
microbiota and consequently host metabolism should be
developed. Oral bacteriotherapy with probiotic organ-
isms might offer a means of modulating both the
intestinal microbial community and host physiology.
The efficacy of probiotics is well-established in the
prevention of antibiotic-associated diarrhea [46]. Future
research will reveal if the promise of probiotics holds
true for the risk of obesity.
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